Background: Two recent randomized trials produced discordant results when testing the benefits and harms of treatment to reduce blood pressure (BP) in patients with cardiovascular disease (CVD).
H igh blood pressure (BP) remains a leading risk factor for cardiovascular disease (CVD) in the United States (1) . Recently, 2 large randomized trials investigated the effect of treating patients with high BP and high CVD risk who received intensive therapy (systolic BP [SBP] target <120 mm Hg) or standard therapy (SBP target <140 mm Hg). The results of the 2 trials differed in their CVD mortality outcomes. In the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study (2) , published in 2010 (n = 4733), patients randomly assigned to intensive therapy, compared with standard therapy, did not have reductions in the primary composite outcome of CVD events (hazard ratio [HR] , 0.88 [95% CI, 0.73 to 1.06]) or CVD mortality (HR, 1.06 [CI, 0.74 to 1.52]). In SPRINT (Systolic Blood Pressure Intervention Trial) (3), published in 2015 (n = 9361), patients randomly assigned to intensive therapy had both clinically and statistically significant reductions in CVD events (HR, 0.75 [CI, 0.64 to 0.89]) and CVD mortality (HR, 0.57 [CI, 0.38 to 0.85]). Although the relative risk reduction in CVD events observed in the trials (12% in ACCORD vs. 25% in SPRINT) did not differ significantly, differences in the relative risk reduction in CVD mortality were statistically significant (6% increase in ACCORD vs. 43% decrease in SPRINT; P < 0.05) (Supplement Table 1, available at Annals.org).
Experts interpreting the results of these 2 trials have proposed several theories for the differences. Although the results may differ by chance alone, this seems unlikely given the large sample sizes and large differences in effects observed between the trials. Another possible explanation is that persons with diabetes (enrolled in ACCORD) may not benefit from intensive BP control, but those without diabetes (enrolled in SPRINT) do. However, prior studies discount this possibility (4) . For example, the HOT (Hypertension Optimal Treatment) trial (n = 18 790) (5) found benefits from intensive therapy only among participants with diabetes. Alternative theories attribute the differences in trial outcomes to differences in other sample characteristics (the average age of participants was greater in SPRINT, 
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which included those with chronic kidney disease-a group that was excluded from ACCORD), outcome definitions (heart failure was included in the overall CVD composite outcome in SPRINT but not ACCORD), or BP measurement technique (SPRINT protocols used a different method of measurement). However, subgroup analyses in SPRINT revealed similar benefits of intensive therapy across ages and kidney function levels that persisted when heart failure was excluded from the outcome definition (3) . Because these analyses are typically underpowered and limited to studying 1 clinical feature at a time (rather than combinations of such features as age, biomarker levels, and CVD risk levels) (6 -12) , clinicians are often left with the dilemma of how best to interpret these conflicting results.
The inability to concretely identify why ACCORD and SPRINT results differ is emblematic of the finding that conventional treat-to-target trials have difficulty providing reliable evidence to decipher heterogeneous treatment effects (HTEs) (13) ; in other words, to identify whether and why some patients have greater or fewer benefits or risks from a therapeutic decision. Uncovering HTEs is critical to clinicians because benefit and risk assessments are required to ensure that individual patients receive the benefits observed in SPRINT while avoiding the potential harms observed in ACCORD.
Two specific causes of HTEs, the number of BP agents provided and the diastolic BP (DBP) achieved, might explain the differences between the trials' outcomes. Treatment in these studies differed markedly in how many BP agents the intensive therapy group received (41% received ≥4 agents in ACCORD vs. 24% in SPRINT) (Table) and DBP achieved (64 mm Hg in ACCORD vs. 69 mm Hg in SPRINT) (2, 3) . Very low DBP has been associated with increased mortality, independent of SBP, in subgroup analyses of both trials and cohort studies (14); analogously, decreasing benefit with increasing medication intensity has been observed because of diminishing effectiveness and increasing polypharmacy (15) . However, we cannot know whether these effects are real, because subgroup analysis of trials neutralize the benefits of randomization, which leads to potentially biased results (16).
We hypothesize that to decipher such HTEs, a SMART (sequential, multiple assignment, randomized trial) may be useful (17) . A SMART design ( Figure 1 ) randomly assigns participants to either be intensified or not be intensified to each additional agent. Hence, the design allows us to examine effects of treatment intensification along the pathway of achieving a target (for example, SBP <120 mm Hg) rather than only compare aggregate outcomes among intensive therapy and control groups. The design is thus intended to overcome a major problem with conventional designs: Participants in each group receive varied treatments in pursuit of the assigned treatment goals (for example, to achieve the target a person in the intensive therapy group could require only 1 medication and someone else could require 4). Heterogeneous treatments in a study group can make it difficult to identify whether some strategies conferred benefit among some participants and harm among others (18) .
Using microsimulation models, we performed a thought experiment to determine whether a priorihypothesized HTEs with strong prior evidence could be hidden in, and explain the conflicting results between, conventional treat-to-target trials. We analyzed whether a conventional treat-to-target trial design, as used in ACCORD and SPRINT, could reliably and accurately detect such HTEs if they exist and, alternatively, whether a SMART design could better identify these potentially hidden HTEs. Figure 3 ). † Reference 2. ‡ Reference 3. § These percentages do not sum to 100, probably due to rounding. ͉͉ ACCORD publications rounded these values to the nearest 1%, whereas SPRINT publications rounded them to the nearest 0.1%.
METHODS
Different amounts and sources of heterogeneity can and probably do exist within trials, independent of the differences or similarities of their overall treatment effects (11). Our objective was to investigate whether large, clinically important HTEs could be hidden in the trials and explain their discordance in overall treatment effects, not what all possible HTEs might be. We provide an overview of the methods, with complete details in the Supplement (available at Annals.org).
Microsimulation Model of ACCORD and SPRINT
To examine whether HTEs could be hidden in the ACCORD and SPRINT trials and could explain the discordant results, we developed a microsimulation model to explain the results of both trials. The model was designed to test the following 2 primary HTEs: treatment to very low DBP could pose harm, offsetting the benefit of treating to lower SBP; and use of many BP agents could pose harm, also offsetting this benefit of treating to lower SBP. The model simulated each participant in each group of each trial, their reported clinical features and BP agents received, and subsequent CVD events and deaths (Table) . Because individual-participant trial data were not available for this analysis, we simulated the patient characteristics (pre-and posttreatment SBP and DBP, Framingham risk score, and number of agents used) to match summary statistics from each trial publication. We also performed repeated simulations across the range of input values reported to capture the range of uncertainty. The CVD events were defined as coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, or heart failure.
We created 3 simple models incorporating only a few key variables supported by prior theory or empirical evidence. Specifically, our models estimated the HR of CVD events and CVD deaths between the 2 groups of each trial as a function of 5 variables: pretreatment and posttreatment SBP, posttreatment DBP, number of BP agents used, and 10-year pretreatment Framingham CVD risk score (19) . In model 1, we considered all 5 variables. Next, we calibrated models that omitted the number of BP agents used (model 2) and another that omitted DBP after treatment (model 3). We calibrated each model to find the variable coefficients that al- 
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Heterogeneous Blood Pressure Treatment Response lowed it to simultaneously match the HRs for CVD events and deaths for both trial populations. Using the calibrated models, we estimated the degree to which individual participants receiving intensive therapy could differ in their expected benefits and risks for intensification and still fit both sets of trial results.
SMART Design Simulation
We then simulated a SMART trial with sequential randomization to increasingly intensive BP therapy (Figure 1) to estimate potential benefits and risks at each stage of intensification. This analysis used aggregate trial participant data and models calibrated to ACCORD and SPRINT and specified the BP reductions for each medication based on a prior meta-analysis (20). Inclusion criteria were age 50 to 75 years, 10-year Framingham CVD risk score of 10% or greater, SBP of 135 to 150 mm Hg and DBP of 65 to 100 mm Hg when receiving 1 or 2 BP agents, and no history of congestive heart failure. The correlations among age, risk score, SBP, and DBP were taken from the National Health and Nutrition Examination Survey (2013 to 2014) to account for the correlations between risk factors (that is, increased SBP with age) (21).
Three randomizations were simulated ( Figure 1 ): a subset of participants receiving 1 BP agent were randomly assigned to either continue their regimen or add a second agent; those receiving 2 agents who did not achieve SBP less than 120 mm Hg were randomly assigned to either continue their regimen or add a third agent; and those receiving 3 BP agents who did not achieve an SBP less than 120 mm Hg were randomly assigned to either continue their regimen or add a fourth agent. Hence, the SMART design still supports treatment to the SBP target of 120 mm Hg, but it randomly assigned participants to increase or continue their number of BP agents in pursuit of the target.
Eligibility for randomization to the next more intensive phase of therapy was based on the average of 2 simulated measurements of BP (with a coefficient of variation of 0.09 to capture measurement error and biological variation across clinical recordings) (22, 23). We adopted an intention-to-treat approach to estimate HRs of treatment effect. Our primary outcome metric was the HR of CVD events from each stage of intensified treatment (Supplement). The secondary outcome metric was CVD mortality.
Power Calculations for Treat-to-Target and SMART Designs
To examine how large a trial would need to be to achieve greater than 80% power to identify clinically important HTEs, we simulated conventional treat-totarget and SMART trials with sample sizes varying from 2000 to 20 000 participants. Concordant with current recommendations for detecting HTEs (11, 24) , power was defined as the percentage of 10 000 repeated simulations at a given sample size that produced a significant logistic regression coefficient (2-tailed P < 0.05 level) for the interaction term of the treatment group (0 if standard or 1 if intensive) and 1 of the following: number of BP agents before intensification (1, 2, or 3) or DBP less than 70 mm Hg (0 if >70 mm Hg) before intensification. For each of 10 000 trials simulated at each sample size, we sampled with replacement from the probability distributions of all input parameters (Supplement) to estimate the degree of random variation and uncertainty in the outcome rates. We then compared the estimated HTE size and power of the conventional treat-to-target trials with the SMART trials at each sample size. All modeling was performed in R, version 3.1.2 (R Foundation for Statistical Computing).
The study was deemed exempt from ethics panel review by the Stanford University Institutional Review Board (e-protocol ID 34359).
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RESULTS
Microsimulation Model of ACCORD and SPRINT
Using the trial characteristics of each study group (Table) , our microsimulation models showed that clinically important HTEs by DBP and number of agents could explain the differences in CVD events and CVD deaths between ACCORD and SPRINT. As shown in Figure 2 , the fitted HTE equations predicted that the benefits of intensified therapy decreased when posttreatment DBP was less than 70 mm Hg or more BP agents were added. (See the Supplement for full equations, which also included variables for pretreatment and posttreatment SBP and pretreatment CVD risk.) For example, a person treated to 60 mm Hg would be expected to have an HR of CVD events that is 0.08 higher than someone treated only to 65 mm Hg. Further, a person requiring 4 BP agents would be expected to have an HR of CVD events that is 0.20 higher than someone achieving the same SBP target with 3 BP agents. We illustrated the DBP of 70 mm Hg as a prespecified cut point to match prior BP-lowering trials (14). The HTE by pretreatment CVD risk was small because of limited variation in CVD risk among the 2 trials in which all participants were at high risk. Supplement Figure 1 shows that our models closely approximated both the mean and CIs around the HRs of CVD events and CVD deaths in both trials. Alternative models that examined HTE by low DBP (model 2) or number of BP agents (model 3), but not both, could similarly explain the differences between ACCORD and SPRINT results.
Supplement Table 2 shows how clinically important the amount of HTE reported in Figure 2 
Statistical Power to Detect HTE of a Conventional Clinical Trial Versus SMART Design
These results only demonstrate that clinically important HTE could explain the differences in ACCORD and SPRINT, but they cannot address whether true, clinically important HTEs could reliably be found in these trials. Therefore, we next examined whether the large HTEs in Figure 2 would probably be detected by subgroup analyses of conventional treat-to-target trial designs, such as those used for ACCORD and SPRINT. As shown in Figure 3 , the conventional treat-to-target trial designs would have less than 5% power to detect the HTEs, even with sample sizes of 20 000 participants (2.9% power for DBP and 3.9% power for number of BP agents). In simpler models in which we limited major HTE to only low DBP (Supplement Figure 3, A) or only the number of BP agents (Supplement Figure 3, B) , the power did not substantially improve.
In contrast, we found that a SMART trial design would have greater than 80% power to detect HTE by the number of BP agents with a sample size as small as 3500 participants (Figure 3 ). This type of trial would need to have a substantially larger sample size of 16 200 participants to have greater than 80% power to detect the theorized HTE by DBP (<70 mm Hg). If a single HTE was dominant (Supplement Figure 3, A and  B) , the required sample sizes would decrease modestly (approximately 14 700 to detect HTE in DBP and 3400 to detect HTE in the number of agents).
Further analysis identified the main reason that conventional treat-to-target trials have less power to detect HTEs. Each study group has a wide range of starting values for DBP and BP agents. This made it difficult for the conventional design to detect which factors in each group were contributing to benefits or harms (that is, the participants in each group were very different, which reduced the ability to have sufficient power to identify the HTE) (Supplement Figure 4) . In addition, the proportion of participants who were randomly assigned to a similar number of additional BP agents but differed in their prerandomization DBP or prerandomization number of BP agents was severely imbalanced, which reduced the effective sample size to detect the HTEs in the treat-to-target design (Supplement Figure 5) . Specifically, the simulations showed that no participants in the standard therapy group received 3 or more additional agents and no participants in the intensive therapy group received 0 additional agents or only 1 additional agent. Thus, the only contrast involving participants in both groups was among those who received 2 additional agents (Supplement Figure 5) . In contrast, the SMART trial randomly assigned similar participants to more or less intensive therapy. This allowed for better identification of which factors contributed to benefits or harms and a more balanced sample size during comparison of participants who were randomly assigned to a similar number of additional BP agents but differed with respect to prerandomization DBP or number of BP agents before intensification. Of note, the conventional treat-to-target trial design produced estimates biased toward the null for HTE sizes. In contrast, the SMART trial design produced unbiased point estimates of the HTE sizes (Supplement Figure 6 ).
DISCUSSION
Traditional treat-to-target trial designs have great intuitive appeal. Participants are randomly assigned to treatment targets, such as a specific SBP goal, and agents are advanced in pursuit of that goal. If the trial is successful and subgroup analyses fail to show HTEs, then it is generally assumed that the results can be For simplicity of presentation, the HTE for DBP is presented as binary, but it was modeled as a continuous function. (See the Supplement, available at Annals.org, for the full equations fitted to the results of both ACCORD and SPRINT; these equations also adjust for pretreatment and posttreatment systolic BP and pretreatment CVD risk.) Effects were estimated by simulating patients who met the trial inclusion criteria and plotting the distribution of anticipated HRs among them after calibration of the HR parameters to both ACCORD and SPRINT summary statistics. The CIs were estimated by repeating the simulation 10 000 times while sampling with replacement from the probability distributions of all input parameters (Supplement). ACCORD = Action to Control Cardiovascular Risk in Diabetes trial; BP = blood pressure; CVD = cardiovascular disease; DBP = diastolic blood pressure; HR = hazard ratio; HTE = heterogeneous treatment effect; SPRINT = Systolic Blood Pressure Intervention Trial.
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safely generalized to all persons who met the trial's inclusion criteria (3). Our findings raise doubts about these assumptions. We found that large and clinically important HTEs can be hidden in conventional treat-totarget designs. Trial designs that use sequential randomization are much better at detecting such HTEs and potentially provide better evidence to guide personalized treatment. Conflicting results from treat-to-target trials are not limited to BP studies. They also are found in diverse fields in which treatment to biomarker levels is used to guide such treatment as that of type 2 diabetes to achieve a specific hemoglobin A 1c target (25) . The primary issue with the conventional treat-totarget design is the heterogeneity of the treatment received by patients in the same study group and its potential influence on outcomes. For example, in SPRINT's intensive therapy group, some patients received 2 agents whereas others ultimately required at least 4 agents. Similarly, in ACCORD's intensive therapy group, some patients had DBP decreased to less than 55 mm Hg and others had a final DBP greater than 75 mm Hg. A treat-to-target trial design cannot reliably examine HTEs. Because these heterogeneous treatment advances occur after randomization, we cannot match intensive treatment patients who needed fewer or more agents to achieve the SBP goal to the appropriate control patients.
Our analysis focused on 2 of the largest, most rigorously designed trials of SBP treatment intensification that had similar designs but produced different results. However, our general findings are relevant to all randomized, controlled trials that involve treatment intensification protocols. Subgroup analyses, including those in individual-level meta-analyses, have known limitations in helping clinicians translate their results to individual patients (6 -12) . Our results further demonstrate that treat-to-target randomized, controlled trials have inherent, yet poorly appreciated, additional deficiencies that can hide HTEs that occur in the treatment pathway. Of note, we observed that a trial with reasonable sample size and sequential randomization can detect hypothesized HTEs by deciphering risk and benefit along the pathway of treatment intensification. In addition, a treat-to-target trial would not be expected to detect large and clinically important HTEs. It would be expected to produce biased HTE size estimates if HTEs were detected at all.
As with any study relying on modeling, our study is limited by its assumptions. We explored only HTEs by the number of agents, not by drug classes, and we did not include the possibility of independent effects of diabetes on CVD risk or the importance of different choices in SBP measurement or CVD outcome definitions. Greater access to individual-level trial data may help test some of HTEs theorized in our study, which are based on summary statistics alone. However, we found that HTE analysis of individual-level trial data from a treat-to-target trial would likely be biased. Of note, treat-to-target designs are inherently limited for assessing whether HTEs are hidden in such trials, which makes explaining why trials yielded different results potentially difficult.
Although all HTE examinations require a priori specification (12, 23) , sequential randomization is uniquely capable of allowing the examination of such issues. The SMART design may be helpful in analyzing HTEs and identifying which patients may benefit or face risks as a target is pursued. Our trial design can detect HTEs in characteristics that can be randomized (such as the number of BP agents) or are directly affected by the characteristic being randomized (such as DBP), but not necessarily all HTEs. However, the SMART design would add complexity to the conduct of clinical trials and would be less straightforward to analyze.
In conclusion, large and clinically important HTEs, such as benefit decreasing as more BP agents are added or harm occurring from low DBP, could be hidden in the SPRINT and ACCORD trials and could explain their discordant results. Trials using a treat-totarget design would have very poor statistical power to detect such HTEs and thus would produce biased results. In contrast, a large clinical trial using a sequential randomization design would have good to excellent Results are based on the SMART study design shown in Figure 1 and a conventional treat-to-target design of a representative U.S study population with the following characteristics: age 50 to 75 y, 10-y Framingham CVD risk score ≥10%, SBP of 135 to 150 mm Hg and DBP of 65 to 100 mm Hg when receiving 1 or 2 BP agents, and no history of congestive heart failure. The specified HTEs for power calculations are those found in a microsimulation model that is fitted to both ACCORD and SPRINT results (see Supplement Figure 2 and equation 1 in the Supplement, both available at Annals.org). The dashed lines show where 2 of the lines (those pertaining to the number of agents and DBP in SMART) achieved 80% power. ACCORD = Action to Control Cardiovascular Risk in Diabetes trial; BP = blood pressure; CVD = cardiovascular disease; DBP = diastolic blood pressure; HTE = heterogeneous treatment effect; SBP = systolic blood pressure; SMART = sequential, multiple assignment, randomized trial; SPRINT = Systolic Blood Pressure Intervention Trial.
Heterogeneous Blood Pressure Treatment Response RESEARCH AND REPORTING METHODS statistical power for detecting and correctly estimating HTEs and thus would provide better clinical evidence for optimal, personalized prescribing of BP agents.
